Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Brigette Ma(Chinese University of Hong Kong), Anthony T.�C. Chan(Chinese University of Hong Kong), Nathan R. Foster(University Health Network), Alex Y. Chang(Cornell University), Christine H. Chung(Moffitt Cancer Center), Charles Erlichman(Roswell Park Comprehensive Cancer Center), Ann D. King(College of American Pathologists), Mark Agulnik(Northwestern University), Edwin P. Hui(Johns Hopkins University), Wan‐Teck Lim(National Cancer Centre Singapore), Boon Cher Goh(National University of Singapore), Barbara J. Gitlitz(University of Southern California), Ka‐Fai To(Chinese University of Hong Kong), Douglas R. Adkins(Washington University in St. Louis), Julie A. Kish(Moffitt Cancer Center), Kwok Wai Lo(Chinese University of Hong Kong), Brian A. Costello(Mayo Clinic in Arizona), K.C. Allen Chan(Rubicon Biotechnology (United States)), Jonathan W. Riess(University of California Davis Medical Center), Jun Yin(Mayo Clinic), Adam Pettinger(Johns Hopkins University), Dean Lim(Cleveland Clinic), Yuk Ming Dennis Lo(Chinese University of Hong Kong), Kevin J. Cullen(University of Maryland, Baltimore), Akhil Chopra(Johns Hopkins University)
Cited by 473
Related Papers
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k